Immunotoxins and Toxin Constructs in the Treatment of Leukemia and Lymphoma

Advances in Pharmacology

Volumn 51, Issue , 2004, Pages 209-228

  Rosenblum, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; TOXIN;

ANIMAL; CHEMISTRY; DRUG SCREENING; LEUKEMIA; LYMPHOMA; REVIEW; SYNTHESIS;

ANIMALS; IMMUNOTOXINS; LEUKEMIA; LYMPHOMA; TOXINS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 16544374300     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(04)51009-8     Document Type: Article

References (113)

1. R.L. Alexander G.L. Kucera B. Klein A.E. Frankel In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin⧸IL-3 fusion protein Bioconj. Chem 11 2000 564 568
2. P.L. Amlot M.J. Stone D. Cunningham J. Fay J. Newman R. Collins R. May M. McCarthy J. Richardson V. Ghetie A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy Blood 82 1993 2624 2633
3. S.F. Atkinson T. Bettinger L.W. Seymour J.P. Behr C.M. Ward Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells J. Biol. Chem 276 2001 27930 27935
4. R. Baluna E.S. Vitetta An in vivo model to study immunotoxin-induced vascular leak in human tissue J. Immunother 22 1999 41 47
5. A.E. Bendel Y. Shao S.M. Davies B. Warman C.H. Yang K.G. Waddick F.M. Uckun J.P. Perentesis A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor Leuk. Lymph 25 1997 257 270
6. G. Bérgamaschi V. Perfetti L. Tonon A. Novella C. Lucotti M. Danova M. Glennie G. Merlini M. Cazzola Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis Br. J. Haematol 93 1996 789 794
7. I.D. Bernstein CD33 as a target for selective ablation of acute myeloid leukemia Clin. Lymph 2 Suppl. 1 2002 S9 S11
8. A. Bolognesi L. Polito P.L. Tazzari R.M. Lemoli C. Lubelli M. Fogli L. Boon M. de-Boer F. Stirpe In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins Br. J. Haematol 110 2000 351 361
9. M.A. Bonardi R.R. French P. Amlot G. Gromo D. Modena M.J. Glennie Delivery of saporin to human B-cell lymphoma using bispecific antibody: Targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing Cancer Res 53 1993 3015 3021
10. M. Bregni S. Siena A. Formosa D.A. Lappi D. Martineau F. Malavasi B. Dorken G. Bonadonna A.M. Gianni B-cell restricted saporin immunotoxins: Activity against B-cell lines and chronic lymphocytic leukemia cells Blood 73 1989 753 762
11. C. Burbage E.P. Tagge B. Harris P. Hall T. Fu M.C. Willingham A.E. Frankel Ricin fusion toxin targeted to the human granulocyte-macrophage colony-stimulating factor receptor is selectively toxic to acute myeloid leukemia cells Leuk. Res 21 1997 681 690
12. P.C. Caron L. Dumont D.A. Scheinberg Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia Clin. Cancer Res 4 1998 1421 1428
13. C.H. Chan B.R. Blazar C.R. Eide R.J. Kreitman D.A. Vallera A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells Blood 86 1995 2732 2740
14. J.Y. Chu A.D. Yang B.M. Wang Z. Hu X.M. Zhu H.J. Zhang J.H. Qu L.Y. Luo R. Guo L.R. Shi Monoclonal anti-human T cell antibody and PAP-s conjugate: Preparation and selective cytotoxic properties on leukemic cell J. Tongji Med. Univ 10 1990 15 18
15. R.M. Conry M.B. Khazaeli M.N. Saleh V. Ghetie E.S. Vitetta T. Liu A.F. LoBuglio Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: Effect of an intensive schedule of administration J. Immunother. Emphasis. Tumor Immunol 18 1995 231 241
16. P.C. Dedon A.A. Salzberg J. Xu Exclusive production of bistranded DNA damage by calicheamicin Biochemistry 32 1993 3617 3622
17. L. Delprino M. Giacomotti F. Dosio P. Brusa M. Ceruti G. Grosa L. Cattel Toxin-targeted design for anticancer therapy. II. Preparation and biological comparison of different chemically linked gelonin-antibody conjugates J. Pharm. Sci 82 1993 699 704
18. D. Douer New advances in the treatment of acute promyelocytic leukemia Int. J. Hematol 76 Suppl. 2 2002 179 187
19. J. Drak N. Iwasawa S. Danishefsky D.M. Crothers The carbohydrate domain of calicheamicin gamma I1 determines its sequence specificity for DNA cleavage Proc. Natl. Acad. Sci. USA 88 1991 7464 7468
20. P. Engel N. Wagner A.S. Miller T.F. Tedder Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand J. Exp. Med 181 1995 1581 1586
21. A. Engert F. Burrows W. Jung P.L. Tazzari H. Stein M. Pfreundschuh V. Diehl P. Thorpe Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease Cancer Res 50 1990 84 88
22. A. Engert C. Gottstein H. Bohlen U. Winkler G. Schon O. Manske R. Schnell V. Diehl P. Thorpe Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice Int. J. Cancer 63 1995 304 309
23. A. Falasca A. Gasperi-Campani A. Abbondanza L. Barbieri F. Stirpe Properties of the ribosome-inactivating proteins gelonin, Momordica charantia inhibitor, and dianthins Biochem. J 207 1982 505 509
24. E. Feldman M. Kalaycio G. Weiner S. Frankel P. Schulman L. Schwartzberg J. Jurcic E. Velez-Garcia K. Seiter D. Scheinberg D. Levitt N. Wedel Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195 Leukemia 17 2003 314 318
25. M. Feuring-Buske A. Frankel B. Gerhard D. Hogge Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells Exp. Hematol 28 2000 1390 1400
26. D.J. Flavell D.A. Boehm A. Noss S.L. Warnes S.U. Flavell Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin Br. J. Cancer 84 2001 571 578
27. A.E. Frankel B.L. Powell P.D. Hall L.D. Cawe R.J. Kreitman Phase I trial of a novel diptheria toxin⧸granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia Clin. Cancer Res 8 2002 1004 1013
28. A.E. Frankel D.R. Fleming P.D. Hall B.L. Powell J.H. Black C. Leftwich R. Gartenhaus A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia Clin. Cancer Res 9 2003 3555 3561
29. A.E. Frankel D.R. Fleming B.L. Powell R. Gartenhaus DAB(389)IL2 (ONTAK((R))) fusion protein therapy of chronic lymphocytic leukaemia Expert Opin. Biol. Ther 3 2003 179 186
30. A.E. Frankel P.D. Hall C. Burbage J. Vesely M. Willingham K. Bhalla R.J. Kreitman Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein Blood 90 1997 3654 3661
31. R.R. French C.A. Penney A.C. Browning F. Stirpe A.J. George M.J. Glennie Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies Br. J. Cancer 71 1995 986 994
32. M.A. Ghetie R.D. May M. Till J.W. Uhr V. Ghetie P.P. Knowles M. Relf A. Brown P.M. Wallace G. Janossy Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy Cancer Res 48 1988 2610 2617
33. M.A. Ghetie K. Tucker J. Richardson J.W. Uhr E.S. Vitetta The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin Blood 80 1992 2315 2320
34. P.H. Gosselaar A.J. van Dijk G.C. de Gast L. Polito A. Bolognesi W.C. Vooijs A.F. Verheul H.G. Krouwer J.J. Marx Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation Eur. J. Clin. Invest 32 Suppl. 1 2002 61 69
35. J.D. Griffin D. Linch K. Sabbath P. Larcom S.F. Schlossman A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells Leuk. Res 8 1984 521 534
36. R. Gunther L.M. Chelstrom D. Finnegan L. Tuel-Ahlgren J.D. Irvin D.E. Myers F.M. Uckun In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia⧸lymphoma in mice with severe combined immunodeficiency Leukemia 7 1993 298 309
37. P.D. Hall R.J. Kreitman M.C. Willingham A.E. Frankel Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL⧸6 mice Toxicol. Appl. Pharmacol 150 1998 91 97
38. P.D. Hall B.I. Razzouk T.E. Willoughby T.W. McLean A.E. Frankel The majority of children and adolescents with acute myeloid leukemia have detectable anti-DT388-GMCSF IgG concentrations, but at concentrations that should not preclude in vivo activity J. Pediatr. Hematol. Oncol 24 2002 521 526
39. P.D. Hall G. Virella T. Willoughby D.H. Atchley R.J. Kreitman A.E. Frankel Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony-stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia Clin. Immunol 100 2001 191 197
40. P. Harris E. Reed D.W. King N. Suciu-Foca In vitro studies of the effect of MAb NDA 4 linked to toxin on the proliferation of a human EBV-transformed lymphoblastoid B cell line and of gibbon MLA leukemia cell line Cell Immunol 134 1991 85 95
41. D.E. Hogge C.L. Willman R.J. Kreitman M. Berger P.D. Hall K.J. Kopecky C. McLain E.P. Tagge C.J. Eaves A.E. Frankel Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein Blood 92 1998 589 595
42. Y.W. Huang F.J. Burrows E.S. Vitetta Cytotoxicity of a novel anti-ICAM-1 immunotoxin on human myeloma cell lines Hybridoma 12 1993 661 675
43. M. Huhn S. Sasse M.K. Tur B. Matthey T. Schinkothe S.M. Rybak S. Barth A. Engert Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma Cancer Res 61 2001 8737 8742
44. M. Hursey D.L. Newton H. Hansen D. Ruby D.M. Goldenberg S.M. Rybak Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics Leuk. Lymph 43 2002 953 959
45. S.R. Husain R.J. Kreitman I. Pastan R.K. Puri Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model Nat. Med 5 1999 817 822
46. K. Ishiguro P.T. Ho A.C. Sartorelli Characterization of the defect in a variant of HL-60 promyelocytic leukemia cells with reduced transferrin receptor expression Somat. Cell Mol. Genet 18 1992 45 63
47. B.H. Joshi P. Leland J. Silber R.J. Kreitman I. Pastan M. Berger R.K. Puri IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4- Pseudomonas exotoxin fusion protein Br. J. Cancer 86 2002 285 291
48. J.G. Jurcic T. DeBlasio L. Dumont T.J. Yao D.A. Scheinberg Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia Clin. Cancer Res 6 2000 372 380
49. T. Kiyokawa K. Shirono T. Hattori H. Nishimura K. Yamaguchi J.C. Nichols T.B. Strom J.R. Murphy K. Takatsuki Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia Cancer Res 49 1989 4042 4046
50. R.J. Kreitman Toxin-labeled monoclonal antibodies Curr. Pharm. Biotechnol 2 2001 313 325
51. R.J. Kreitman Recombinant toxins for the treatment of cancer Curr. Opin. Mol. Ther 5 2003 44 51
52. R.J. Kreitman I. Margulies M. Stetler-Stevenson Q.C. Wang D.J. FitzGerald I. Pastan Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias Clin. Cancer Res 6 2000 1476 1487
53. R.J. Kreitman I. Pastan Immunobiological treatments of hairy-cell leukaemia Best Pract. Res. Clin. Haematol 16 2003 117 133
54. R.J. Kreitman Q.C. Wang D.J. FitzGerald I. Pastan Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys Int. J. Cancer 81 1999 148 155
55. R.J. Kreitman W.H. Wilson K. Bergeron M. Raggio M. Stetler-Stevenson D.J. FitzGerald I. Pastan Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia N. Engl. J. Med 345 2001 241 247
56. J.S. Kristensen P. Hokland Monoclonal antibodies in myeloid diseases: Prognostic use in acute myeloid leukaemia Leuk. Res 15 1991 693 700
57. C.F. LeMaistre F.E. Craig C. Meneghetti B. McMullin K. Parker J. Reuben D.H. Boldt M. Rosenblum T. Woodworth Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers Cancer Res 53 1993 3930 3934
58. A.L. Lindstrom S.L. Erlandsen J.H. Kersey C.A. Pennell An in vitro model for toxin-mediated vascular leak syndrome: Ricin toxin A chain increases the permeability of human endothelial cell monolayers Blood 90 1997 2323 2334
59. T.C. Liu G.B. Tan C.L. Wong P. Han Immunophenotypic characterisation of monocytoid differentiation markers in acute non-lymphoblastic leukaemias Ann. Acad. Med. Singapore 20 1991 353 355
60. I.A. Lorimer C.J. Wikstrand S.K. Batra D.D. Bigner I. Pastan Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors Clin. Cancer Res 1 1995 859 864
61. E. Mansfield P. Amlot I. Pastan D.J. FitzGerald Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors Blood 90 1997 2020 2026
62. E. Mansfield M.F. Chiron P. Amlot I. Pastan D.J. FitzGerald Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells Biochem. Soc. Trans 25 1997 709 714
63. E. Mansfield I. Pastan D.J. FitzGerald Characterization of RFB4- Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies Bioconj. Chem 7 1996 557 563
64. J. Marcil N. Ravindranath M.R. Sairam Cytotoxic activity of lutropin-gelonin conjugate in mouse Leydig tumor cells: Potentiation of the hormonotoxin activity by different drugs Mol. Cell Endocrinol 92 1993 83 90
65. D.Y. Mason W.M. Comans-Bitter J.L. Cordell M.A. Verhoeven J.J. van Dongen Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen Am. J. Pathol 136 1990 1215 1222
66. R.D. May E.S. Vitetta G. Moldenhauer B. Dorken Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins Cancer Drug Deliv 3 1986 261 272
67. M.S. McGrath M.G. Rosenblum M.R. Philips D.A. Scheinberg Immunotoxin resistance in multidrug resistant cells Cancer Res 63 2003 72 79
68. K.J. McGraw M.G. Rosenblum L. Cheung D.A. Scheinberg Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias Cancer Immunol. Immunother 39 1994 367 374
69. K. Mehta L. Ocanas F. Malavasi J.W. Marks M.G. Rosenblum Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells Mol. Cancer Ther 3 2004 345 352
70. Y. Messinger Y. Yanishevski V.I. Avramis O. Ek L.M. Chelstrom R. Gunther D.E. Myers J.D. Irvin W. Evans F.M. Uckun Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside Clin. Cancer Res 2 1996 1533 1542
71. D.E. Myers F.M. Uckun An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia Leuk. Lymphoma 18 1995 119 122
72. C. Nabhan M.S. Tallman Early phase I⧸II trials with gemtuzumab ozogamicin (Mylotarg®) in acute myeloid leukemia Clin. Lymph 2 Suppl. 1 2002 S19 S23
73. J. Nichols F. Foss T.M. Kuzel C.F. LeMaistre L. Platanias M.J. Ratain A. Rook M. Saleh G. Schwartz Interleukin-2 fusion protein: An investigational therapy for interleukin-2 receptor expressing malignancies Eur. J. Cancer 33 Suppl. 1 1997 S34 S36
74. M. O'Hare A.N. Brown K. Hussain A. Gebhardt G. Watson L.M. Roberts E.S. Vitetta P.E. Thorpe J.M. Lord Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence FEBS Lett 273 1990 200 204
75. R.K. Oldham M. Lewis D.W. Orr B. Avner S.K. Liao J.R. Ogden B. Avner R. Birch Adriamycin custom-tailored immunoconjugates in the treatment of human malignancies Mol. Biother 1 1988 103 113
76. L.C. Pagliaro B. Liu R. Munker M. Andreeff E.J. Freireich D.A. Scheinberg M.G. Rosenblum Humanized M195 monoclonal antibody conjugated to recombinant gelonin: An anti-CD33 immunotoxin with antileukemic activity Clin. Cancer Res 4 1998 1971 1976
77. I. Pastan Immunotoxins containing Pseudomonas exotoxin A: A short history Cancer Immunol. Immunother 52 2003 338 341
78. K. Psarras M. Ueda M. Tanabe M. Kitajima S. Aiso S. Komatsu M. Seno Targeting activated lymphocytes with an entirely human immunotoxin analogue: Human pancreatic RNase1-human IL-2 fusion Cytokine 12 2000 786 790
79. M.J. Robertson R.J. Soiffer A.S. Freedman S.L. Rabinowe K.C. Anderson T.J. Ervin C. Murray K. Dear J.D. Griffin L.M. Nadler Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia Blood 79 1992 2229 2236
80. G.J. Roboz M.A. Knovich R.L. Bayer M.W. Schuster K. Seiter B.L. Powell R.D. Woodruff R.T. Silver A.E. Frankel E.J. Feldman Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia Leuk. Lymph 43 2002 1951 1955
81. M.G. Rosenblum L. Cheung S.K. Kim K. Mujoo N.J. Donato J.L. Murray Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells Cancer Immunol. Immunother 42 1996 115 121
82. M.G. Rosenblum W.A. Kohr K.L. Beattie W.G. Beattie W. Marks P.D. Toman L. Cheung Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum J. Interferon Cytokine Res 15 1995 547 555
83. M.G. Rosenblum J.W. Marks L.H. Cheung Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin Cancer Chemother. Pharmacol 44 1999 343 348
84. H. Rozemuller P.S. Chowdhury I. Pastan R.J. Kreitman Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated Pseudomonas exotoxin Int. J. Cancer 92 2001 861 870
85. E.A. Sausville D. Headlee M. Stetler-Stevenson E.S. Jaffe D. Solomon W.D. Figg J. Herdt W.C. Kopp H. Rager S.M. Steinberg Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study Blood 85 1995 3457 3465
86. D.A. Scheinberg M. Tanimoto S. McKenzie A. Strife L.J. Old B.D. Clarkson Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia Leukemia 3 1989 440 445
87. G.L. Shen J.L. Li M.A. Ghetie V. Ghetie R.D. May M. Till A.N. Brown M. Relf P. Knowles J.W. Uhr Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas Int. J. Cancer 42 1988 792 797
88. Y.K. Shin Y.L. Choi E.Y. Choi M.K. Kim M.C. Kook J. Chung Y.K. Choi H.S. Kim H.G. Song S.H. Park Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications Cancer Immunol. Immunother 52 2003 506 512
89. H. Shinohara S. Morita M. Kawai A. Miyamoto T. Sonoda I. Pastan N. Tanigawa Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin J. Surg. Res 102 2002 169 177
90. S. Siena M. Bregni A. Formosa B. Brando P. Marenco D.A. Lappi G. Bonadonna A.M. Gianni Immunotoxin-mediated inhibition of chronic lymphocytic leukemia cell proliferation in humans Cancer Res 49 1989 3328 3332
91. D. Simmons B. Seed Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells J. Immunol 141 1988 2797 2800
92. E.A. Stadtmauer Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia Curr. Oncol. Rep 4 2002 375 380
93. F. Stirpe S. Olsnes A. Pihl Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A J. Biol. Chem 255 1980 6947 6953
94. T.B. Strom V.R. Kelley J.R. Murphy J. Nichols T.G. Woodworth Interleukin-2 receptor-directed therapies: Antibody- or cytokine-based targeting molecules Annu. Rev. Med 44 1993 343 353
95. E.B. Sweeney F.M. Foss J.R. Murphy J.C. vanderSpek Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: A novel agent for the elimination of IL-7 receptor positive cells Bioconj. Chem 9 1998 201 207
96. M. Talpaz K. Hagop E. Freireich V. Lopez W. Zhang J. Cortes-Franco D. Scheinberg M.G. Rosenblum Phase I clinical trial of the anti-CD-33 immunotoxin HuM195⧸rGel Proceedings of the AACR. Cadmus Professional Communications, Linthicum, MD, Abstract # 5362, 44, 1228. 2003
97. M. Tanimoto D.A. Scheinberg C. Cordon-Cardo D. Huie B.D. Clarkson L.J. Old Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195 Leukemia 3 1989 339 348
98. P.L. Tazzari S. Zhang Q. Chen S. Sforzini A. Bolognesi F. Stirpe H. Xie A. Moretta S. Ferrini Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin⧸anti-CD25 bispecific monoclonal antibody: In vitro evaluation Br. J. Cancer 67 1993 1248 1253
99. A. Terenzi A. Bolognesi L. Pasqualucci L. Flenghi S. Pileri H. Stein M. Kadin B. Bigerna L. Polito P.L. Tazzari M.F. Martelli F. Stirpe B. Falini Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice Br. J. Haematol 92 1996 872 879
100. J. Thorburn A.E. Frankel A. Thorburn Apoptosis by leukemia cell-targeted diphtheria toxin occurs via receptor-independent activation of Fas-associated death domain protein Clin. Cancer Res 9 2003 861 865
101. P.E. Thorpe A.N. Brown W.C. Ross A.J. Cumber S.I. Detre D.C. Edwards A.J. Davies F. Stirpe Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin Eur. J. Biochem 116 1981 447 454
102. K. Toba H. Hanawa I. Fuse M. Sakaue K. Watanabe Y. Uesugi W. Higuchi M. Takahashi Y. Aizawa Difference in CD22 molecules in human B cells and basophils Exp. Hematol 30 2002 205 211
103. P.A. Trail H.D. King G.M. Dubowchik Monoclonal antibody drug immunoconjugates for targeted treatment of cancer Cancer Immunol. Immunother 52 2003 328 337
104. C.S. Viele Gemtuzumab ozogamicin Clin. J. Oncol. Nurs 6 2002 298 299 304
105. E.S. Vitetta M. Stone P. Amlot J. Fay R. May M. Till J. Newman P. Clark R. Collins D. Cunningham Phase I immunotoxin trial in patients with B-cell lymphoma Cancer Res 51 1991 4052 4058
106. I.A. Voutsadakis Gemtuzumab ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia Anticancer Drugs 13 2002 685 692
107. T.A. Waldmann The interleukin-2 receptor on normal and malignant lymphocytes Adv. Exp. Med. Biol 213 1987 129 137
108. T.A. Waldmann The role of the multichain IL-2 receptor complex in the control of normal and malignant T-cell proliferation Environ. Health Perspect 75 1987 11 15
109. T.G. Woodworth J.C. Nichols Recombinant fusion toxins—a new class of targeted biologic therapeutics Cancer Treat. Res 68 1993 145 160
110. Y. Xu Q. Xu M.G. Rosenblum D.A. Scheinberg Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice Leukemia 10 1996 321 326
111. P.T. Yazdi R.M. Murphy Quantitative analysis of protein synthesis inhibition by transferrin-toxin conjugates Cancer Res 54 1994 6387 6394
112. N. Zein A.M. Sinha W.J. McGahren G.A. Ellestad Calicheamicin gamma 1I: An antitumor antibiotic that cleaves double-stranded DNA site specifically Science 240 1988 1198 1201
113. H. Zola S.H. Neoh A. Potter J.V. Melo M.S. De Oliveria D. Catovsky Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules Dis. Markers 5 1987 227 235